(0.07%) 5 476.98 points
(0.09%) 38 812 points
(-0.02%) 17 854 points
(0.27%) $80.55
(0.65%) $2.81
(0.14%) $2 332.20
(-0.29%) $29.31
(-0.05%) $970.40
(0.03%) $0.932
(-0.16%) $10.64
(0.05%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 371 |
Vidutinė apimtis | 31 926 |
Rinkos kapitalizacija | 37.93M |
EPS | $-0.710 ( Q1 | 2024-03-31 ) |
Kita pelno data | ( $-0.630 ) 2024-08-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.240 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0420 (1.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-09-07 | Zukiwski Alexander A | Buy | 3 000 | Employee Stock Option (Right to Buy) |
2022-09-06 | Huang James | Buy | 33 300 | Common Stock |
2022-08-31 | Huang James | Buy | 400 | Common Stock |
2022-08-24 | Huang James | Buy | 39 527 | Common Stock |
2022-08-19 | Huang James | Buy | 40 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 95 transactions |
Buy: 27 815 562 | Sell: 9 916 643 |
CASI Pharmaceuticals Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
TTEC | 0.951 |
UONEK | 0.944 |
CNXC | 0.938 |
UONE | 0.935 |
OFS | 0.935 |
RETO | 0.93 |
TWKS | 0.929 |
ARKO | 0.928 |
NEPH | 0.928 |
AMPH | 0.926 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
OZEM | -1 |
MNMD | -0.94 |
BKHAR | -0.94 |
ROOT | -0.929 |
RNA | -0.929 |
ARYD | -0.924 |
BNR | -0.923 |
DXPE | -0.92 |
FANG | -0.92 |
AIRG | -0.919 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
CASI Pharmaceuticals Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $33.88M |
Bruto pelnas: | $18.98M (56.03 %) |
EPS: | $-2.02 |
FY | 2023 |
Pajamos: | $33.88M |
Bruto pelnas: | $18.98M (56.03 %) |
EPS: | $-2.02 |
FY | 2022 |
Pajamos: | $43.11M |
Bruto pelnas: | $27.28M (63.28 %) |
EPS: | $-2.89 |
FY | 2021 |
Pajamos: | $30.17M |
Bruto pelnas: | $17.61M (58.38 %) |
EPS: | $-0.332 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.